ARDS is an acute, severe lung injury that causes edema of the lung alveoli, leading to breathing abnormalities and insufficient oxygen levels in the circulating blood, which may be life-threatening owing to respiratory failure and/or multi-organ dysfunction. ARDS may be caused by sepsis, trauma, severe pneumonia, or inhalation of harmful substances and it is associated with a high mortality rate. No pharmacological therapy is specifically approved for ARDS and treatment is supportive, principally comprising nonpharmacological approaches (e.g., mechanical ventilation, oxygen supplementation). There is unmet need and thus commercial opportunity for effective pharmacotherapies that can reduce patients’ reliance on ventilation and the mortality associated with ARDS. Apart from Faron Pharmaceuticals/Maruishi Pharmaceuticals’ intravenous interferon beta-1a (Traumakine), the ARDS pipeline comprises largely early- to mid-stage agents with diverse mechanisms of action (e.g., Apeptico/Mediolanum Farmaceutici’s sodium channel modulator solnatide).
How will the size of the ARDS population change through 2026? What are the key drug targets emerging from basic and clinical research in ARDS?
Which emerging therapies do ARDS experts consider most promising? How would new therapies influence management of ARDS patients?
How are emerging ARDS drugs being evaluated, and which are likely to launch by 2026? What commercial impact will they have on the ARDS market?
Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.